News By Tag
News By Location
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2022
Nivolumab to Lead Lung Cancer Drug Market with Sales of $1.75 Billion by 2022
According to the company’
Covering the key markets of the US, UK, France, Germany, Italy, Spain and Japan, China and India, GlobalData’
For further details, please click or add the below link to your browser:
Brooke Baker, PhD, oncology healthcare analyst with GlobalData, says: “NSCLC is the second most common cancer in both men and women, and patients who are diagnosed with the condition have an extremely poor prognosis, with five-year survival rates limited to approximately 2% in US patients diagnosed at stage four of the disease.
With BMS seeking to position the drug in the second line for all NSCLC patients, it could well fulfil two significant unmet needs within disease management: as a superior second-line therapy and as a treatment for squamous patients. Expected entry of nivolumab in the first-line setting in 2019 will cement the leading position of BMS’s strong asset, states the report.
Considering these advantages, GlobalData believes that nivolumab will become a key driver behind the growth of the global NSCLC market, which is expecting to rise at a Compound Annual Growth Rate (CAGR) of 3.3%, from $5.7 billion in 2012 to $7.9 billion in 2022.
“This level of growth will also result from an increasing number of NSCLC incident cases in the majority of the markets covered by the report, especially in Japan and the emerging markets of China and India,”
NOTES TO EDITORS
This forecast provides an overview of Non-Small Cell Lung Cancer, and includes an in-depth analysis of historical trends for lung cancer incidence, mortality, and survival; smoking prevalence, disease stage at diagnosis, and the status of lung cancer screening programs in each market. This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’
GlobalData is the premier source of actionable insight into the energy and healthcare industries. With the combined expertise of more than 1,000 researchers, market analysts and consultants, we provide high-quality, accurate and transparent industry insightthat helps our clients to achieve growth and increase business value.
Visit our report store: http://store.globaldata.com/
For more details contact:pressreleases@
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
Page Updated Last on: Jul 16, 2013